Headlines

Ofatumumab With Fludarabine, Cyclophosphamide Approved for Relapsed CLL

Ofatumumab With Fludarabine, Cyclophosphamide Approved for Relapsed CLL

The US Food and Drug Administration has approved ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of relapsed chronic lymphocytic leukemia (CLL).

Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion

Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion

Treatment with ibrutinib is associated with a high overall response rate in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and 17p deletion.

Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera

Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera

Ruxolitinib is an effective long-term treatment option for patients with polycythemia resistant or intolerant to hydroxyurea, according to a study presented at the 2016 European Hematology Association Congress.

Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC

Patients with head and neck cancer treated with IMRT had a significantly shorter duration of feeding tube placement compared with those who received 3DRT.

SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC

Continued adoption of stereotactic body radiation therapy (SBRT) to treat early stage NSCLC improved OS and lung cancer-specific survival, according to a study presented at the 2016 annual meeting of the American Society for Radiation Oncology.

Patients Receiving RT in APBI Facilities Despite Eligibility for Observation

Patients Receiving RT in APBI Facilities Despite Eligibility for Observation

Patients with early stage breast cancer who received breast-conserving surgery and were eligible for observation were more likely to undergo adjuvant radiotherapy in facilities performing APBI.

Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response

Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response

In patients with chronic myeloid leukemia in chronic phase, prolonged treatment with imatinib helps to achieve a deeper molecular response over 5 years.

TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI

TKI-intolerant Patients With CLL Can Successfully Receive an Alternate TKI

Patients with chronic lymphocytic leukemia (CLL) who discontinue TKI therapy due to toxicity can successfully be treated with an alternate TKI.

ASCO, ASTRO Issue Guideline Update for Postmastectomy RT

ASCO, ASTRO Issue Guideline Update for Postmastectomy RT

The American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology have issued a joint consensus guideline update for the use of radiotherapy following mastectomy in patients with breast cancer.

Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score

Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score

In patients with advanced HCC and a baseline αFP level of 400 ng/mL or more, a survival benefit with second-line ramucirumab therapy was observed for those with Child-Pugh scores of 5 and 6.

Conference Coverage

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.

CT-Based Technique for Body Mass Measurements of Patients With Cancer Improves Disease Staging, Therapy Monitoring

A new method of measuring lean body mass accounts for changes in body composition, enabling improved disease staging and monitoring of therapy.

Overall Survival and Progression-Free Survival Are Improved With Ibrutinib for del17p CLL

Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.

Premedication With Antiemetic Improves Length of Stay and Readmissions for a Liver Cancer Procedure

Including an antiemetic in the preprocedure medications for patients with liver cancer undergoing drug eluting bead chemoembolization (DEB TACE) can shorten hospital stays and reduce the chance for readmission due to complications.

Imaging Technique Is Predictive of Immunotherapy Response in Non-Small Cell Lung Cancer

Results from phase II trial on the use of FDG-PET to evaluate the efficacy of an immunotherapy drug in the treatment of NSCLC.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs